Everest Organics Limited submitted outcome of Board meeting held on November 12, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited financial results for the quarter and half year ended September 30, 2025, along with the Limited Review Report from statutory auditors P.S.N. Ravishanker & Associates. Revenue from operations grew strongly to Rs. 3,867.66 lakhs in H1 FY26 versus Rs. 2,774.72 lakhs in H1 FY25, an increase of roughly 39%. Profit after tax also improved sharply, rising to around Rs. 264.93 lakhs from Rs. 119.26 lakhs in the comparable prior period. However, the auditor issued a QUALIFIED review report flagging two serious concerns: (1) the company is operating at production levels beyond those approved by the Telangana State Pollution Control Board without proper consents, creating a going concern risk if a closure order is enforced, and (2) Rs. 143 lakhs of interest claimed by suppliers on delayed payments has not been provided for in the books, understating liabilities and overstating profit. Net cash from operating activities was negative at Rs. (253.73) lakhs for the half year.
Despite strong top-line and bottom-line growth, the auditor's qualifications around going concern status and unrecorded supplier liabilities of Rs. 143 lakhs are material red flags that may weigh on the stock. Investors should view the headline profit growth with caution given the regulatory non-compliance risk and understated expenses.